Overview
Rallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024
Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024
Co sells REV102 interest for up to $25 mln, extending cash runway
Outlook
Rallybio expects RLYB116 study data in 3Q and 4Q 2025
Company's cash runway extended into mid-2027 after REV102 sale
Rallybio anticipates complete complement inhibition in RLYB116 study
Company focuses RLYB116 on PTR and APS conditions
Result Drivers
REVENUE DECLINE - Decrease in revenue attributed to changes in collaboration agreements with Johnson & Johnson
R&D EXPENSES DROP - Lower R&D expenses due to decreased development costs for RLYB212 and other programs
CASH INFUSION - Sale of REV102 interest to Recursion Pharmaceuticals extends cash runway into mid-2027
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | -$9.70 mln | ||
Q2 Basic EPS | -$0.22 | ||
Q2 Income From Operations | -$10.06 mln | ||
Q2 Operating Expenses | $10.27 mln |
Press Release: ID:nBw38yYrla
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。